Kite’s CAR T-Cell Therapy Yescarta^®. Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma

Kite announced that the European Commission has approved its CAR T-cell therapy Yescarta® for the treatment of adult patients with relapsed or refractory follicular lymphomaafter three or more lines of systemic therapy.